The assessment of mesenchymal stem cells therapy in acute on chronic liver failure and chronic liver disease: a systematic review and meta-analysis of randomized controlled clinical trials.

Stem Cell Res Ther · 2022 · PMC9109309 · PMID 35578365

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

However, it should be noted that there was no difference in MELD score at 48 weeks and even an increasing trend after MSCs therapy.

also in 63,971 other papers

showed a trendno p-value reported

However, it showed a trend of a higher survival rate at each stage of treatment, and the pooled OR indicated a significant increase in the survival rate in patients with MSCs therapy (OR 1.29, 95% CI 1.03–1.60; P = 0.023) (Fig. 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.